



Atty. Dkt. No. 039363-0703

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ryan Bremer et al.

Title:

CRYSTAL STRUCTURE OF

PIM-1 KINASE


Appl. No.:

10/664,421

Filing Date: 09/16/2003

Examiner:

Art Unit:



INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment-IDS Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English. The references were cited in an International Search Report from related international application No. PCT/US2003/06477. Some of the references cited in the report (5,763,198; Al-Obeidi et al. and Lipinski) were previously disclosed to the USPTO and are therefore not included on the attached SB08.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 CFR §1.704(d) that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR §1.56(c) more than thirty days prior to the filing of the information disclosure statement.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

FOLEY & LARDNER LLP

Customer Number: 30542 Telephone:

(858) 847-6767

Facsimile:

(858) 792-6773

Richard J. Warburg Attorney for Applicant Registration No. 32,327

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paper ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Aumber.

RADEMAT	Substitute for form	1449B	/PTO		Complete if Known
	INFORMATION DI	SCLO	SURE	Application Number	10/664421
	STATEMENT BY	APPLI	CANT	Filing Date	9/16/03
				First Named Inventor	Bremer
				Group Art Unit	1656
(use as many sheets	as ne	cessary)	Examiner Name	Nashed
Sheet	1	of	2	Attorney Docket Number	039363-0703

				U.S. PATENT DOCUMENTS	6		
Examiner Initials*	Cite No. ¹	U.S. Patent I	Document		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines,	
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document		Where Relevant Passages or Relevant Figures Appear	
	A1	5698401		Fesik et al.	12-16-1997		
	A2	5804390		Fesik et al.	09-08-1998		
	A3	6297021		Nienaber et al.	10-02-2001		

	U.S. PATENT APPLICATION DOCUMENTS							
Examiner Cite Initials* No.	Cito	U.S. Patent Application Document		N	Filing Date of	Pages, Columns, Lines, Where Relevant		
		Serial Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	F Office	oreign Patent [³ Number ⁴	Oocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁶		
	A4	WO	99/63931		The Salk Institute for Biological Studies	12-16-1999				
						·		 		

NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ^f						
	A5	Ashani and Wilson, A covalent affinity column for the purification of acetylcholinesterase. Biochem. Biophys. Acta, 276:317-322, 1972.							
	A6	Feinberg et al., Zinc-directed inhibitors for zinc proteinases. Acta Cryst., D51: 428-449, 1995.							

بسسون				
Examiner Signature			Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for	r form 1449B	/PTO	Complete if Known			
	INFORMATIO	ON DISCLO	SURE	Application Number	10/664421		
	STATEMENT	BY APPL	ICANT	Filing Date	9/16/03		
				First Named Inventor	Bremer		
				Group Art Unit	1656		
	(use as many s	heets as ne	ecessary)	Examiner Name	Nashed	-	
Sheet	2	of	2	Attorney Docket Number	039363-0703		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т ⁶
	A7	Fitzgerald et al., Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. The Journal of Biological Chemistry, 265 (24): 14209-14219, 1990.	
	A8	Geller et al., HIV-1 protease and its inhibitors in Theoretical and Computational Mthods in Genome Research. Edited by Sahai. New York: Plenum Press, 1997, p. 237-254.	
	A9	Kleinberg and Wanke, New approaches and technologies in drug design and discovery. Am. J. Health-Syst Pharm., 52: 1323-1336, 1995.	
	A10	McPherson et al., The Role of X-ray crystallography in structure-based rational drug designs. Chapter 6 in Chemical Structures Approaches Ration. Drug Design. Edited by D.V. Weiner et al. Boca Raton: CRC Press, 1995, p. 161-179.	
	A11	Rosenberry et al., Purification of acetylcholinesterase by affinity chromatography and determination of active site stoichiometry. The Journal of Biological Chemistry, 247 (5): 1555-15565, 1972.	
	A12	Sica et al., Affinity chromatography and the purification of estrogen receptors. The Journal of Biological Chemistry, 248 (18): 6543-6558, 1973.	
	A13	Wuthrich, NMR-This other method for protein and nucleic acid structure determination. Acta Cryst., D51: 249-270, 1995.	

Examiner	•	Date	· ·
Signature		Considered	
Olginature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.